Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42


When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators..

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.


Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.


Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.

Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, Kaplan JE, Doherty MC.

Lancet HIV. 2015 Apr;2(4):e137-50. doi: 10.1016/S2352-3018(15)00005-3. Epub 2015 Mar 3. Review.


Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD004772.


Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.

Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.

Cochrane Database Syst Rev. 2013 Oct 10;(10):CD010309. doi: 10.1002/14651858.CD010309.pub2. Review.


The lifetime cost of current human immunodeficiency virus care in the United States.

Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore RD, Freedberg KA.

Med Care. 2006 Nov;44(11):990-7. Review.


Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.


Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.

Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, Nachega JB.

Ann Intern Med. 2015 Jul 7;163(1):32-9. doi: 10.7326/M14-2979. Review.


Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.

Chang LW, Harris J, Humphreys E.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008494. doi: 10.1002/14651858.CD008494. Review.


Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

When To Start Consortium., Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR.

Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Review.


[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.


Economic evaluation of ART in resource-limited countries.

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y.

Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d. Review.


[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida..

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.


Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis.

Munthali C, Taegtmeyer M, Garner PG, Lalloo DG, Squire SB, Corbett EL, Ford N, MacPherson P.

J Int AIDS Soc. 2014 Jun 12;17:18932. doi: 10.7448/IAS.17.1.18932. eCollection 2014. Review.


Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review.

Saadani Hassani A, Marston BJ, Kaplan JE.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S257-69. doi: 10.1097/QAI.0000000000000486. Review. Erratum in: J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):e84.


Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.

Lawn SD, Török ME, Wood R.

Curr Opin Infect Dis. 2011 Feb;24(1):34-42. doi: 10.1097/QCO.0b013e3283420f76. Review.


HIV treatment and care in resource-constrained environments: challenges for the next decade.

Eholié SP, Aoussi FE, Ouattara IS, Bissagnéné E, Anglaret X.

J Int AIDS Soc. 2012 Aug 22;15(2):17334. doi: 10.7448/IAS.15.2.17334. Review.


Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis.

Suthar AB, Granich R, Mermin J, Van Rie A.

Bull World Health Organ. 2012 Feb 1;90(2):128C-138C. doi: 10.2471/BLT.11.093260. Epub 2011 Oct 24. Review.


Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.

Eholié SP, Badje A, Kouame GM, N'takpe JB, Moh R, Danel C, Anglaret X.

AIDS Res Ther. 2016 Jul 26;13:27. doi: 10.1186/s12981-016-0111-1. eCollection 2016. Review.


'Test-and-treat': the end of the HIV epidemic?

Cambiano V, Rodger AJ, Phillips AN.

Curr Opin Infect Dis. 2011 Feb;24(1):19-26. doi: 10.1097/QCO.0b013e3283422c8c. Review.


Supplemental Content

Support Center